Ubs Group Ag Tarsus Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 27,973 shares of TARS stock, worth $927,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,973

Previous 38,340 27.04%

Holding current value

$927,304

Previous $1.39 Million 45.44%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$25.17 - $38.73 $260,937 - $401,513	-10,367 Reduced 27.04%	27,973 $760,000
Q1 2024 May 13, 2024	BUY	$19.61 - $39.22 $153,879 - $307,759	7,847 Added 25.73%	38,340 $1.39 Million
Q4 2023 Feb 09, 2024	BUY	$12.98 - $20.73 $149,166 - $238,229	11,492 Added 60.48%	30,493 $617,000
Q3 2023 Nov 09, 2023	BUY	$14.75 - $24.62 $22,700 - $37,890	1,539 Added 8.81%	19,001 $337,000
Q2 2023 Aug 11, 2023	BUY	$11.57 - $19.63 $108,815 - $184,620	9,405 Added 116.73%	17,462 $315,000
Q1 2023 May 12, 2023	BUY	$11.92 - $16.27 $14,292 - $19,507	1,199 Added 17.48%	8,057 $101,000
Q4 2022 Feb 08, 2023	BUY	$14.12 - $18.72 $86,950 - $115,277	6,158 Added 879.71%	6,858 $100,000
Q2 2022 Aug 10, 2022	SELL	$11.08 - $19.08 $39,068 - $67,276	-3,526 Reduced 83.44%	700 $10,000
Q1 2022 May 16, 2022	BUY	$14.49 - $24.28 $16,547 - $27,727	1,142 Added 37.03%	4,226 $71,000
Q4 2021 Feb 14, 2022	BUY	$21.21 - $29.68 $54,806 - $76,693	2,584 Added 516.8%	3,084 $70,000
Q3 2021 Nov 15, 2021	BUY	$21.45 - $29.22 $10,725 - $14,610	500 New	500 $11,000
Q2 2021 Aug 13, 2021	SELL	$27.16 - $38.59 $67,791 - $96,320	-2,496 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$27.37 - $47.25 $32,050 - $55,329	1,171 Added 88.38%	2,496 $80,000
Q4 2020 Feb 11, 2021	BUY	$19.17 - $49.62 $25,400 - $65,746	1,325 New	1,325 $55,000

Others Institutions Holding TARS

# of Institutions

155

Shares Held

40.4M

Call Options Held

37.9K

Put Options Held

808K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $884M
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account